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Purpose: To employ response surface methodology (RSM) for statistical optimization of formulation 
factors in the preparation of celecoxib-loaded microspheres. 
Methods: Celecoxib microspheres were prepared by solvent evaporation method. 
Biodegradable/biocompatible polymers, Eudragit L-100 and polyvinyl pyrrolidone, were used in the 
encapsulation procedure. A central composite design employing Stat-Ease design Expert®, version 
7.0.3 having a unit value of α was used according to reference protocols to assess the influence of two 
independent variables (i.e., the concentration of the two polymers used) on four dependent variables 
(i.e., recovery, encapsulation efficiency and % drug released). The polymers used were Eudragit-L100 
(X1) and polyvinyl pyrrolidone (X2). The microspheres were characterized for size, shape, recovery (%), 
entrapment efficiency and drug release.  
Results: The recovered total weight of microspheres ranged between 49.4 ± 3.1 and 91.1 ± 4.8 %, and 
it decreased with increase in the concentration of PVP. Entrapment efficiency was in the range of 54.1 ± 
2.9 to 95.6 ± 3.7 %, and was also dependent on polymer concentration. The release of celecoxib 
increased with decrease in Eudragit L-100 concentration and increase in PVP concentration. Higuchi 
model was the best-fit drug release from all the formulations. Korsemeyer-Peppas release exponent (n) 
indicates that drug release pattern was non-Fickian diffusion. 
Conclusion: Using RSM, it is possible to optimize the drug release properties of celecoxib-loaded 
microspheres. A celecoxib-loaded microsphere formulation with optimum recovery, entrapment 
efficiency and release behavior was proposed. 
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INTRODUCTION 
 
Response surface methodology (RSM) is a 
collection of mathematical and statistical 
techniques for the modeling and analysis of 
problems in which a response of interest is 
influenced by variables and the objective is to 
optimize this response [1]. It has been 
applied to pharmaceutical systems and 
particulate carriers such as gelispheres, 
matrices and microspheres. It is necessary to 
have a clear understanding of how 
preparation conditions and inherent 
characteristics of excipients employed in 
pharmaceutical preparations are influenced 
by potential interaction between various 
factors in order to optimize a formulation 
[2,3]. 
  
Formulations based on microspheres provide 
optimum control of kinetics of drug release 
from the dosage form [4]. Controlled release 
preparations are preferred as these produce 
maximum therapeutic effect with a low risk of 
adverse effects [5]. Biodegradable polymers 
degrade within the body as a result of natural 
biological processes, and therefore, there is 
no need to eliminate the delivery system after 
its function is over [6]. Hence, microspheres 
made with biodegradable polymers, are 
useful as controlled release (CR) systems. 
Several methods are being used for the 
preparation of microspheres both from 
natural and synthetic polymers [7]. 
 
Celecoxib is used for pain, osteoarthritis, 
rheumatoid arthritis, painful menstruation  
and to reduce the number of colon and rectal 
polyps in patients. It is approximately 10 - 20 
times more selective for COX-2 inhibition 
than COX-1 [8-10]. 
 
The aim of this study was to prepare an 
optimized microparticulate formulation of 
celecoxib employing solvent evaporation 
technique to elaborate the influence of 
specific combinations of two polymers, i.e. 
Eudragit L-100 and polyvinyl pyrrolidone, on 
the release behavior of the drug. Since RSM 
with polynomial equations is helpful in the 
rapid development of an optimum formulation 
with minimum number of experiments for the 
investigation of the influence of the 
independent variables on results, this 
approach was employed in this study to 
obtain an optimized microparticulate 
formulation of celecoxib as well as to assess 







Celecoxib (99.8 %) and Eudragit L-100 were 
donated by IRZA Pharmaceutical, Lahore, 
Pakistan. Polyvinyl pyrrolidone (PVP) was a 
gift from Pharma-wise, Lahore, Pakistan, 
respectively. All other chemicals used - light 
liquid paraffin (BDH, UK), acetone and n-
hexane (Merck, Germany), and Tween 80 
(Sigma, USA) - were of analytical grade. 
 
Preparation of microspheres 
 
Microspheres were prepared by solvent 
evaporation technique. Different ratios of 
Eudragit L-100/polyvinyl pyrrolidone (PVP) 
were dissolved in 40 ml acetone using a 
magnetic stirrer. Celecoxib was dispersed in 
the polymer solution and stirred for 15 min. 
The resulting dispersion was mechanically 
added in a thin stream to a mixture of 360 ml 
light liquid paraffin, 0.5% Tween-80 and 40 
ml n-hexane contained in a 500 ml beaker. 
Stirring at 700 rpm was continued for 3 h, 
until the acetone evaporated completely. The 
microspheres formed were collected by 
filtration on Whatman filter paper no.1 and 
washed 4 - 5 times with n-hexane [11]. The 
product was then air-dried at room 
temperature for 12 h. Formulations were 
coded as F1, F2, F3, F4, F5, F6, F7, F8, F9, 
F10, F1, F12 and F13, respectively, as per 
Table 1. All the batches were prepared in 
triplicate (n = 3). The experiments were 
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Table 1: Factor combination, based on 








PVP ratio  
-2 0 F1 2:2:5 
-1 -1 F2 2:4:3 
-1 1 F3 2:4:7 
0 -2 F4 2:6:1 
0 0 F5 2:6:5 
0 2 F6 2:6:9 
1 -1 F7 2:8:3 
1 1 F8 2:8:7 
2 0 F9 2:10:5 
0 0 F10 2:6:5 
0 0 F11 2:6:5 
0 0 F12 2:6:5 
0 0 F13 2:6:5 
 
Table 2:  Translation of coded levels in actual 
units 
 
Coded levels -2 -1 0 1 2 
X1  : Eudragit-L100 2 4 6 8 10 




A central composite design having a unit 
value of α was applied according to reference 
protocols [12] to assess the influence of two 
independent variables (i.e., the concentration 
of the two polymers used) on three 
dependent variables [i.e., recovery (Y1), 
encapsulation efficiency (Y2) and percent 
drug released (Y3)]. The polymers used were 
Eudragit-L100 (X1) and polyvinyl pyrrolidone 
(X2). All other formulation and process 
parameters were kept constant during the 
study. Stat-Ease design Expert®, version 
7.0.3, was employed to generate and 
evaluate the statistical experimental design 
and construction of a design matrix with 13 
experimental trials. The response variables 
were evaluated by following second order 
polynomial model, as in Eq 1 
 
Y = βo + β1X1 + β2X2 + β3X1X2 + β4X12 + β5X22 ….. (1) 
 
where, βo – β5 represents regression 
coefficients, X1 –X2 the studied variables and 
Y the measured response with each factor 
level combination (Table 1). Variable 
combinations selected on the basis of the 
experimental design and translation of coded 
levels in actual units are given in Tables 1 
and 2, respectively. 
 
Morphology and size of microspheres 
 
Optical microscope (Erma, Japan) fitted with 
a digital camera (Yashica, Japan) was used 
to measure directly the size of 200 
microspheres by taking their photographs 
and then evaluating the mean diameter [13]. 
Scanning electron microscope (Hitachi, 
Japan) was employed to determine external 
morphology by mounting the microspheres 
on the stubs, applying thin coating of gold 
and taking the photographs (operating 
voltage 15 KV and working distance 20 nm) 
[13]. 
 
Recovery of microspheres 
 
After preparation, the microspheres were 
recovered and dried overnight at room 
temperature. Recovery is the ratio of the 
weight of microspheres recovered to the total 
weight of solid ingredients charged at the 





The dried microspheres (50 mg) were 
dispersed in 10 ml phosphate buffer (pH 6.8); 
it was placed in an ultrasonic bath for 15 min 
and then filtered through a 0.22 mm millipore 
filter (Suzhou Hyford Machinery Company, 
China). The absorbance of the filtrate was 
taken at 251 nm using a UV/Vis 
spectrophotometer (model 1601, Shimadzu, 
Japan) to determine the amount of celecoxib 
present in the microspheres. Drug loading 
was determined as the ratio of the amount of 
drug in the microspheres to the weight of the 
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Entrapment efficiency 
 
Entrapment efficiency can be determined as 
the ratio of actual drug loading to the 
theoretical drug loading, expressed as a 
percentage. 
 
In vitro drug release study 
 
In vitro release studies on the drug-loaded 
microspheres were carried out both at gastric 
and intestinal pH, i.e., pH 1.2 and 7.4, 
respectively [14] using United States 
Pharmacopeial (USP) paddle method. The 
microspheres (700 mg) were placed in 900 
mL dissolution medium and tested first in HCl 
buffer (pH 1.2) for 2 h and then in phosphate 
buffer (pH 7.4) for 12 h. The temperature was 
maintained at 37.0 ± 0.5 °C and the stirring 
speed at 100 rpm. Samples (3 mL) were 
withdrawn and replaced with an equal volume 
of fresh dissolution medium at regular time 
intervals, filtered through 0.45 μm nylon disc 
filter (Suzhou Hyford Machinery Company, 
China) and analyzed spectrophotometrically 
(model 1601, Shmadzu, Japan) at 254 nm 
[14]. The concentration of celecoxib in the 
samples was determined from a standard 
calibration) curve. The dissolution studies 
were carried out in triplicate.  
 
Drug release kinetic analysis 
 
Drug release kinetics indicates the 
mechanism of drug release from drug 
delivery systems. Four kinetic models - zero 
order, first order, Higuchi and Korsemeyer-
Peppas represented as Eqs 2 – 5, 
respectively - were applied to analyze the in 
vitro drug release data to determine the best-
fit release model [13].  
 
Ft = Kot ………………………. (2) 
 
where “Ft” is the fraction of drug released in 
time “t” and “Ko” is the zero-order release 
constant. 
In (1 - F) = -K1t ………………. (3) 
where “F” is the fraction of drug released in 
time “t” and “K1” is the first-order release 
constant. 
 
FH = K2 t1/2 ……………….. (4) 
 
where “FH” is the fraction of drug released in 
time “t” and “K2” is the Higuchi constant. 
 
Mt / M∞ = K3 tn …………… (5) 
 
where “Mt” and “M∞” are the amount of drug 
released at time “t” and “∞”, respectively, and 
“n” is the diffusional coefficient. In spherical 
matrices, if n <0 .43, diffusion is Fickian, 0.45 
< n < 0.89, diffusion is non-Fickian, and n > 
0.85, case-II (zero order) drug release 




One-way ANOVA was applied to determine 
the significant difference between various 
values using SPSS version 15.0. The level of 




Appearance of microspheres 
 
The microspheres were spherical in shape 
with size range of 10.73 ± 0.97 – 31.29 ± 
1.34 μm. They were white in color and free 
flowing.  
 
Recovery and drug entrapment 
 
The recovered total weight of microspheres 
ranged between 49.4 ± 3.1 and 91.1 ± 4.8 % 
and it decreased with increase in PVP 
content of the formulations (Table 3). 
Entrapment efficiency was in the range 54.1 
± 2.9 and 95.6 ± 3.7 % and was dependent 
on the concentration of the polymer. RSM 
results for response Y1 (% recovery) is given 
in Figure 2. The resultant equation for 
response Y1 is shown in Eq 6. 
 
Y1 = 85.6481 + 2.1358 X1 - 2.4108 X2 - 
0.2312 X1X2 – 0.0246 X12 – 0.2454 X22 …. (6) 
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RSM results for response Y2 (entrapment 
efficiency) is given in Figure 2. The resultant 
equation for response Y2 is given in Eq 7. 
 
Y2 = 37.0947 + 1.7348 X1 + 13.2304 X2 + 
0.0375 X1X2 – 0.1240 X12 – 0.9022 X22 …… 
(7) 
 
In vitro drug release 
 
Drug release from the microspheres 
depended mainly on the type and 
concentration of the polymers used in the 
formulation. Plots of drug release from the 
microspheres against time are sown in Figure 
1. All the formulations displayed sustained 
release pattern with 18 – 40 % released at 
gastric pH in the first 2 h and almost 42 to 93 
% released in the next 12 h. The 
microspheres (F3) containing the highest 
concentration of PVP showed the fastest 
drug release with t50% = 5.37 h, while the 
slowest release of celecoxib was observed for F4 
(t50% = 10.43 h) which contained a higher 
level of Eudragit-L100 than PVP. RSM results 
for response Y3 (% drug release) is given in 
Figure 2. The resultant equation for response 
Y2 is presented in Eq 8. 
 
Y3 = 5.0553 + 0.4851 X1 + 2.3141 X2 + 0.1531 
X1X2 – 1.3954 × 10-2 X12 – 0.0302 X22 … (8) 
 
Table 3: Recovery (%) and entrapment efficiency 









F1 71.1±2.6 81.2±3.7 
F2 82.2±3.4 78.4±4.9 
F3 50.7±4.3 95.6±5.4 
F4 91.1±2.2 54.1±2.5 
F5 73.8±5.5 86.7±3.7 
F6 49.4±3.6 89.8±4.9 
F7 86.9±15.7 76.9±5.3 
F8 51.7±3.9 94.7±2.5 
F9 76.4±2.3 87.6±3.7 
F10 73.0±6.5 87.7±3.8 
F11 73.8±3.2 90.0±2.9 
F12 73.2±5.4 88.1±5.2 
F13 71.9±4.6 84.7±4.3 
For all the formulations, in vitro drug release 
was best fitted to Higuchi model (Table 3) as 
the highest linear regression was obtained 
from this model. Korsemeyer-Peppas release 
exponent (n) data indicate that drug release 
mechanism was non-Fickian diffusion.  
 RSM data for various responses (Y1, Y2, and 
Y3) are given in Figure 2. 
 
 





The method used for the preparation of the 
microspheres successful entrapped 
celecoxib. Surfactant (Tween 80) used at a 
concentration of 0.5 %w/v was sufficient to 
facilitate the production of satisfactory 
microspheres. Attempts made in preliminary 
studies to use lower surfactant 
concentrations failed to yield microspheres 
but rather an aggregated mass was formed. 
Stirring rate also influenced the recovery (%). 
The stirring speed of 700 rpm produced the 
microspheres of optimum size. By increasing 
stirring speed above 700 rpm, there was low 
recovery. This low recovery could be due to 
the formation of smaller microspheres which 
were lost during washings process. 
Decreasing the stirring speed promotes 
aggregation of the microspheres; and causes 
materials to adhere to the walls of beaker, 
thus resulting in low recovery. Similar 
observations have been reported by Giannola 
et al [15] and Varshosaz and Keihanfar [16]. 
Increase in Eudragit L-100 content of the 
microspheres resulted in the significant (p <  
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Table 4: Release kinetics of microspheres 
 
Zero order  First order Higuchi  Korsmeyer–Peppas Formulations t50% (h) 
R2 K0 R2 K1 R2 KH R2 N 
F1 5.81 0.928 8.60 0.943 0.177 0.909 26.376 0.967 0.748 
F2 10.23 0.855 4.986 0.959 0.073 0.945 15.490 0.958 0.637 
F3 5.37 0.813 9.310 0.957 0.230 0.933 29.052 0.947 0.602 
F4 10.43 0.847 4.793 0.953 0.069 0.939 14.912 0.959 0.626 
F5 7.66 0.913 6.524 0.992 0.110 0.934 20.121 0.975 0.697 
F6 5.50 0.875 9.099 0.948 0.208 0.920 28.153 0.953 0.672 
F7 9.51 0.863 5.260 0.968 0.079 0.939 16.334 0.963 0.640 
F8 5.44 0.854 9.193 0.946 0.215 0.922 28.519 0.948 0.649 
F9 8.07 0.888 6.534 0.977 0.102 0.919 19.128 0.957 0.686 
F10 7.65 0.913 6.937 0.992 0.111 0.934 20.149 0.976 0.698 
F11 7.62 0.907 6.560 0.991 0.112 0.934 20.247 0.972 0.691 
F12 7.70 0.909 6.494 0.990 0.110 0.932 20.033 0.973 0.696 
F13 7.57 0.892 6.604 0.988 0.114 0.932 20.416 0.967 0.677 
 
 
Figure 2: Response surface plots illustrating the influence of polymer concentrations on % recovery (A), 
entrapment efficiency (B) and drug release (C) 
 
0.05) decrease in entrapment efficiency. This 
might be as a result of the low drug carrying 
capacity of the polymer.  
 
Drug release from the microspheres 
depended mainly on the type and 
concentration of polymer used in the 
formulation. Formulation batches F3, F6 and 
F8 which had a higher concentration of PVP 
relative to that of Eudragit L-100 showed 
complete (100 %) release of drug over the 14 
h period of the release study. A similar result 
was observed by Babu et al [17] who 
prepared microspheres using cellulose 
acetate butyrate and polyvinyl pyrrolidone. 
PVP is an amorphous polymer and a water-
soluble tertiary amine which swiftly dissolves 
in aqueous environment [17]. It behaves as a 
strong Lewis base. Being biocompatible, it is 
widely employed in the fabrication of drug 
delivery systems. Due to its polar groups, it is 
an efficient proton acceptor; therefore, it can 
easily undergo hydrogen bonding with 
suitable compounds, especially polymers that 
behave as proton donors. The application of 
PVP as polymer matrix has been confirmed 
to possess significant outcomes, including 
enhancement of drug stability [17]. Thus, 
celecoxib release was fastest from 
formulation F3 which contained which 
contained a relatively higher level of PVP. 
 
The microspheres with the highest 
concentration of Eudragit L-100 showed 
slower (10.4 % in the first 2 h) drug release in 
acidic medium (0.1N HCl); however faster 
Shahzad  et al 
Trop J Pharm Res, October 2012;11 (5): 701 
release (17.5% in the next 2 h) occurred in 
phosphate buffer (pH 7.4). This implies that 
Eudragit L-100 provided protection for the 
microspheres in acidic conditions. Eudragit L-
100 is a neutral copolymer of polyethyl-
acrylate, methylmethacrylate and trimethyl-
ammoniumethylmethacrylate chloride [18]. It 
is inert to the content of digestive tract, thus 
does not adversely affect the mucosal lining 
and is commonly use for the development of 
oral drug delivery systems [19]. Its 
degradation is pH dependent, being sparingly 
soluble in acidic medium due to the presence 
of acidic groups such as methacrylic acid 
[18], but soluble in solution medium of pH > 
6.0. Therefore, it is widely used for targeted 
delivery of drugs to the colon [19]. It exhibits 
excellent swelling as a result of which it can 
retard drug release and is therefore used to 
achieve prolonged drug release. This 
probably accounts for the very slow release 
of celecoxib from formulation F4 which 
contained a relatively high concentration of 
Eudragit L-100. 
 
Higuchi was best-fit model for all the 
dissolution data indicating that drug was 
diffusion-controlled. Based on the 
Korsemeyer-Peppas release exponent (n), 
drug release was non-Fickian diffusion. Non-
Fickian release, also termed as anomalous 
release, is a combination of two mechanisms, 
i.e., erosion and diffusion operating 
simultaneously [20].  
 
The outcome of the optimization studies 
indicate that the optimum formulation (F10) is 
the one containing Eudragit-L100/PVP in a 
ratio of 6:5. Its recovery and entrapment 
efficiency (%) were 73.0 ± 6.5 and 87.7 ± 3.8 
%, respectively. It also showed prolonged 
release of drug ( approx. 75 % in 14 h).  
 
Furthermore, regression equation was a 
unique model for the description of responses 
of the experimental parameters employed in 




The results of this study demonstrate that 
RSM is a valuable optimization tool for 
selecting suitable variables. Using RSM, an 
ptimized formulation of celecoxib-loaded 
microspheres was achieved in terms of % 
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